| Non-Small-Cell Lung Cancer (NSCLC) - Drug Pipeline | | | | - Insightful review of the key industry drivers, |
| Analysis and Market Forecasts to 2015 | | | | restraints and challenges. Each trend is independently |
| This is an essential source of information and analysis | | | | researched to provide qualitative analysis of its |
| on the global NSCLC market. The report identifies the | | | | implications. |
| key trends shaping and driving the global NSCLC | | | | - Key topics covered include strategic competitor |
| market. The report also provides insight on the | | | | assessment, market characterization, unmet needs |
| prevalent competitive landscape and the emerging | | | | and implications for future market associated with |
| players expected to bring significant shift in the | | | | NSCLC. |
| market positioning of the existing market leaders. | | | | Reasons to buy |
| Most importantly, the report provides valuable insight | | | | The report will enhance your decision making |
| on the pipeline products within the global NSCLC | | | | capability in a more rapid and time sensitive manner. |
| sector. ( ) | | | | It will allow you to: |
| Scope | | | | - Develop and design your in-licensing and out-licensing |
| The scope of the report includes: | | | | strategies through review of pipeline products and |
| - Annualized global NSCLC market revenues data | | | | technologies and by identifying companies with the |
| from 2000 to 2008, forecast forward for 7 years to | | | | most robust pipeline. |
| 2015. | | | | - Develop business strategies by understanding the |
| - Geographic markets covered in this report include | | | | trends shaping and driving the global NSCLC disease |
| the US, the UK, Italy, Spain, Germany, France, and | | | | market. |
| Japan. | | | | - Drive revenues by understanding key trends, |
| - Pipeline analysis data providing a split across | | | | innovative products and technologies, market |
| different phases, mechanism of action being | | | | segments and companies likely to impact the global |
| developed and emerging trends. Key classes of | | | | NSCLC disease market in future. |
| mechanism of action includes tyrosine kinase | | | | - Formulate effective sales and marketing strategies |
| inhibitors, microtubules, protein kinase inhibitors, cell | | | | by understanding the competitive landscape and by |
| division inhibitors, ERBB3 antagonist, DNA and RNA | | | | analyzing the performance of various competitors. |
| synthesis inhibitors, C-Met or ALK Inhibitors, | | | | - Identify emerging players with potentially strong |
| glutathione S-transferase binders, growth and survival | | | | product portfolio and create effective |
| of MM cells inhibitors, HER2 dimerization inhibitors, | | | | counter-strategies to gain competitive advantage. |
| antiangiogenesis inhibitors, cyclooxygenase-2 (COX-2) | | | | - Organize your sales and marketing efforts by |
| inhibitors, Pan Bcl-2 inhibitors and MUC1 | | | | identifying the market categories and segments that |
| tumor-associated antigens etc. | | | | present maximum opportunities for consolidations, |
| - Analysis of the current and future market | | | | investments and strategic partnerships. |
| competition in the global NSCLC market. Key market | | | | - What’s the next big thing in the global NSCLC |
| players covered are F. Hoffmann-La Roche Ltd, Pfizer | | | | disease market landscape? – Identify, understand |
| Inc., Novartis AG, Sanofi-aventis, Boehringer Ingelheim | | | | and capitalize. |
| GmbH, and Abraxis BioScience, Inc. | | | | |